Marina Tschaika

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

20h-index3.6kcitations57works16.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(40), Hepatocellular Carcinoma Treatment and Prognosis(14), Cancer Research and Treatments(9), Cancer Genomics and Diagnostics(8), Gastric Cancer Management and Outcomes(7)

Publications57 total

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Journal of Thoracic Oncology·2024· 22 citedOpen Access
MA11.05 Nivolumab + Ipilimumab vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS
Journal of Thoracic Oncology·2024Open Access
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Journal for ImmunoTherapy of Cancer·2024· 33 citedOpen Access
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
Journal for ImmunoTherapy of Cancer·2024· 12 citedOpen Access
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology·2023· 50 citedOpen Access
Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (<scp>CheckMate</scp> 040)
Clinical and Translational Science·2023· 13 citedOpen Access
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Journal of Clinical Oncology·2022· 63 citedOpen Access
Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial
Cancer Research·2022· 17 cited
Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Cancer Research·2022· 26 cited
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology·2021· 215 citedOpen Access
Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial
SSRN Electronic Journal·2021· 1 citedOpen Access
Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040
Journal of Hepatology·2020· 4 citedOpen Access
Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study
The Oncologist·2020· 20 citedOpen Access
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Journal of Hepatology·2020· 403 citedOpen Access
O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study
Annals of Oncology·2020· 2 citedOpen Access
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Annals of Oncology·2020· 58 cited
CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Journal of Clinical Oncology·2020· 32 cited
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
Journal of Clinical Oncology·2020· 37 cited
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Journal of Clinical Oncology·2020· 110 cited
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Journal of Clinical Oncology·2018· 615 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Padmanee Sharma(12), Emiliano Calvo(12), Bruno Sangro(12), Patrick A. Ott(11), Dung T. Le(11), Thomas Yau(11), Jaclyn Neely(11), Filippo de Braud(10), Paolo A. Ascierto(10), Masatoshi Kudo(10), Matthias Schroff(9), Manuel Schmidt(9), Johanna C. Bendell(8), Yun Shen(8), Anthony B. El-Khoueiry(8), Petri Bono(7), Dirk Jaeger(7), Christopher Harbison(7), Ignacio Melero(7), Su Pin Choo(7)